title: State of the science in cervical cancer: where we are today and where we need to go.
abstract: Invasive cervical cancer remains an important global cause of death, despite the declining prevalence within the United States. Definitive therapies, including surgical resection of early-stage disease and chemoradiation for locally advanced disease, can be curative. For women who experience local or distant recurrences, the prognosis remains poor and better treatments are required. On July 18, 2013, The Gynecologic Oncology Group sponsored a State of the Science in Cervical Cancer Symposium with experts, researchers, clinicians, and interested stakeholders. This article summarize the progress that has been made, questions that require further investigation, and contemporary genomic findings and innovative treatments that may help inform the next generation of clinical trials for patients with cervical cancer.
authors.affiliation: Gillette Center for Gynecologic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
authors.forename: Don S
authors.initials: DS
authors.lastname: Dizon
authors.forename: Helen J
authors.initials: HJ
authors.lastname: Mackay
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Thomas
authors.forename: Theresa L
authors.initials: TL
authors.lastname: Werner
authors.forename: Elise C
authors.initials: EC
authors.lastname: Kohn
authors.forename: Dina
authors.initials: D
authors.lastname: Hess
authors.forename: Peter G
authors.initials: PG
authors.lastname: Rose
authors.forename: Allan L
authors.initials: AL
authors.lastname: Covens
mesh_terms: D005260:Female; D006801:Humans; D002583:Uterine Cervical Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*
keywords: anti-angiogenesis; cervical cancer; clinical trials; human papillomavirus; immunotherapy; prevention; screening